NASDAQ:OCUL - Ocular Therapeutix Stock Price, Forecast & News

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.01. The biopharmaceutical company had revenue of $0.83 million for the quarter, compared to analyst estimates of $1.09 million. Ocular Therapeutix had a negative net margin of 3,141.58% and a negative return on equity of 383.58%. View Ocular Therapeutix's Earnings History.

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ocular Therapeutix.

6 brokers have issued 1-year price targets for Ocular Therapeutix's shares. Their forecasts range from $3.00 to $24.00. On average, they expect Ocular Therapeutix's share price to reach $8.71 in the next year. This suggests a possible upside of 54.2% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.

News headlines about OCUL stock have trended somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ocular Therapeutix earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Ocular Therapeutix.

Some companies that are related to Ocular Therapeutix include Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Dermira (DERM), Myovant Sciences (MYOV), I-Mab (ARQT), Gossamer Bio (GOSS), Achillion Pharmaceuticals (ACHN), Applied Therapeutics (APLT), Radius Health (RDUS), Cytokinetics (CYTK), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), ImmunoGen (IMGN), Rhythm Pharmaceuticals (RYTM) and Dova Pharmaceuticals (DOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Omeros (OMER), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Melinta Therapeutics (MLNT), Canopy Growth (CGC) and Egalet (EGLT).

Ocular Therapeutix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Deltec Asset Management LLC (4.42%), Man Group plc (1.58%), State Street Corp (1.47%), Geode Capital Management LLC (1.19%), Ieq Capital LLC (0.53%) and Ieq Capital LLC (0.53%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc and Richard L Md Lindstrom. View Institutional Ownership Trends for Ocular Therapeutix.

OCUL stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, FMR LLC, Nottingham Advisors Inc., Mercer Global Advisors Inc. ADV, Goldman Sachs Group Inc. and Barclays PLC. View Insider Buying and Selling for Ocular Therapeutix.

OCUL stock was acquired by a variety of institutional investors in the last quarter, including Ieq Capital LLC, Ieq Capital LLC, Deltec Asset Management LLC, Levin Capital Strategies L.P., Geode Capital Management LLC, Virtu Financial LLC, State Street Corp and California Public Employees Retirement System. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc and Richard L Md Lindstrom. View Insider Buying and Selling for Ocular Therapeutix.

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OCUL stock can currently be purchased for approximately $5.65.

Ocular Therapeutix has a market capitalization of $271.65 million and generates $1.99 million in revenue each year. The biopharmaceutical company earns $-59,980,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe.View Additional Information About Ocular Therapeutix.

The official website for Ocular Therapeutix is http://www.ocutx.com/.

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]